The clonogenic cells of chronic myeloid leukaemia (CML), unlike normal haemopoietic progenitor cells, are resistant to the growth inhibitory eects of the chemokine macrophage in¯ammatory protein-1 alpha (MIP-1a). CML is also relatively resistant to chemotherapy and the disease is dicult to cure using conventional therapeutic routes. CML is associated with increased abl oncogene protein tyrosine kinase (PTK) activity. Here, we have tested the hypothesis that these aberrant responses to MIP1a and the relative resistance to chemotherapy are directly related to this increased abl PTK activity in primitive haemopoietic cells. To do this we have expressed a temperature sensitive abl PTK in a growth factor dependent, multipotent stem cell line (FDCP-Mix) in which growth is normally suppressed by MIP-1a. In FDCP-Mix cells expressing the ts v-abl PTK and grown at the restrictive temperature for PTK activity the cells were relatively sensitive to cytotoxic agents such as cytosine arabinoside and 5-¯uorouracil but MIP-1a could induce growth inhibition and confer some degree of protection from these agents. At the permissive temperature for abl PTK, the cells were relatively resistant to cytotoxic drugs and MIP-1a treatment neither induced growth inhibition nor protected the cells from cytotoxic drug induced cell death. This lack of response to MIP-1a was not due to receptor down modulation as neither the anity nor the number of 125 I-MIP-1a binding sites was altered by activating Abl PTK. However, MIP-1a mediated increases in cytosolic Ca 2+ levels were abrogated by switching cells to the permissive temperature for Abl PTK activity. These data suggest that the relative resistance of CML progenitor cells to therapeutic drugs and the lack of response to MIP1a occurs as a direct consequence of abl PTK activity and involves desensitisation of signal transduction events stimulated by MIP-1a receptors. Thus one contributory mechanism to transformation of primitive haemopoietic cells is abrogation of response to a growth inhibitor.
Introduction
Chemokines are a family of inducible proteins which contain a cysteine-x-cysteine or cysteine-cysteine sequence within their primary structure. Members of the chemokine family have distinct but overlapping biological activities, including stimulating chemotaxis of mature myeloid and lymphoid cells (Oppenheim et al., 1991; Wolpe and Cerami, 1989) . Also, some of these chemokines, including Macrophage In¯ammatory Protein-1a (MIP-1a), have a direct growth inhibitory action on haemopoietic progenitor cells Graham et al., 1990) . Several cell types, including keratinocytes, exhibit a growth inhibitory response to MIP-1a as well as primitive haemopoietic progenitor cells (Parkinson et al., 1993) . MIP-1a acts directly on primitive progenitor cells to inhibit proliferation but it can also enhance the proliferation of more mature progenitor cells (Broxmeyer et al., 1989 (Broxmeyer et al., , 1990 .
The growth suppressive eect of MIP-1a is not observed in primitive progenitor cells from patients with Chronic Myeloid Leukaemia (CML), an acquired clonal haemopoietic stem cell disorder (Chasty et al., 1995; Eaves et al., 1993; Holyoake et al., 1993) although cells from some CML patients have been reported to respond (Broxmeyer et al., 1996; Chasty et al., 1995) . The proliferation of primitive CML progenitor cells in long term marrow culture-based assays and also soft gel colony forming assays is not growth inhibited by MIP-1a, although these leukaemic progenitor cells have been shown to bind biotinylated MIP-1a (Chasty et al., 1995) . This suggests that the coupling between MIP-1a receptor binding and signalling for growth inhibition must be dysfunctional. Based on these data it has been suggested that the abrogation of MIP-1a responses in Ph + cells may be of clinical value in that, compared to normal cells, these leukaemic cells will not be protected from cell cycle speci®c cytotoxic drugs by MIP-1a (Dunlop et al., 1992; Lord et al., 1992) .
CML is characterized by a speci®c chromosomal translocation which results in expression of the constitutively activated bcr-abl protein tyrosine kinase found on the Philadelphia (Ph) chromosome (Ben Neriah et al., 1986; Daley and Ben Neriah, 1991) . Thus, a possible explanation for the aberrant response to MIP-1a is that this occurs as a consequence of constitutive activation of abl PTK activity. To test this hypothesis and to`model' the eects of a disregulated abl protein tyrosine on primitive haemopoietic cells, we have expressed a temperature sensitive abl PTK gene in the IL-3 dependent stem cell line, FDCP-Mix, in which growth is suppressed by MIP-1a (Heyworth et al., 1995) . We found that expression of the abl PTK activity did not lead to growth autonomy nor to a block in the cells undergoing myeloid development. However, expression of the abl PTK did lead to a retardation in progenitor cell development and to a delay in apoptosis on growth factor withdrawal (Spooncer et al., 1994) , eects which resemble the characteristics of Ph + cells from patients with CML (Champlin and Golde, 1985) . As CML progenitor cells are non-responsive to MIP-1a we have now assessed whether the abrogation of response to MIP-1a is directly related to expression of abl PTK activity.
Results and discussion

Abl PTK inhibits apoptosis in FDCP-Mix cells
We have expressed a temperature sensitive abl PTK gene in a growth factor dependent, multipotential stem cell line (FDCP-Mix) (Spooncer et al., 1986) in which growth is normally suppressed by MIP-1a (Heyworth et al., 1995) . These ts-abl FDCP-Mix show a marked increase in the levels of protein tyrosine phosphorylation when grown at the permissive (338C) compared with the non-permissive (38.58C) temperatures although the abl PTK protein is expressed at the same levels at both these temperatures (Spooncer et al., 1994) : the tyrosine kinase activity and not the protein levels are in¯uenced by the temperature shift (Spooncer et al., 1986) .
When we measured the growth factor requirement of these cells for survival and proliferation, the switch to the permissive temperature for abl-PTK activity was not sucient to induce growth factor independence (Table 1) , although there was a delay in apoptosis in the activated abl PTK expressing cells in the absence of IL-3, as previously reported (Bedi et al., 1994; Evans et al., 1993; Kabarowski et al., 1994) . In the presence of IL-3 there was an increase in viable cell number at both the permissive and restrictive temperatures. The rate of increase was suggestive of similar cycling times in both Abl PTK and control cells at 38.58C and 338C. Furthermore,¯ow cytometric cell cycle analysis of control and Abl PTK FDCP-Mix cells cultured with IL-3 for 12 h showed no dierences in the proportion of cells in cycle between any of these populations (see Figure 1) . Importantly, the requirement for growth factors for mitogenic stimulation was maintained at both the restrictive and the permissive temperatures (see Tables 1 and 2 ). [ (Coutinho et al., 1993) of the clonogenic cells (see Figure 3 ): MIP-1a could`protect' normal and abl PTK FDCP-Mix cells grown at the non-permissive temperature, but could only protect the normal and not the abl PTK cells grown at the permissive temperature. In other words, the response of the abl PTK FDCP-Mix cells grown at the permissive temperature recapitulates the results found with CML progenitor cells (Chasty et al., 1995; Eaves et al., 1993; Holyoake et al., 1993) . When other Abl PTK FDCP-Mix clones were used the same results were obtained. These data demonstrate that the abrogation of response to MIP-1a is a consequence of the abl PTK activity and, to our knowledge, represents the ®rst clear example of an oncogene product that directly in¯uences the response of primitive cells to a growth inhibitory stimulus, Indeed, this may well be part of the mechanism whereby CML progenitor cells can preferentially expand, at the expense of normal cells, in the marrow (Dexter and Chang, 1994) .
The Abl PTK protects FDCP-Mix cells from the cytotoxic eects of cell cycle speci®c drugs
We next examined the eect of abl PTK on the ability of MIP-1a (Gao et al., 1993; Neote et al., 1993) to protect cells from cell cycle active drugs (Major et al., 1981; Parker and Cheng, 1990) . In preliminary experiments we determined that approximately 50% of cells were killed with a cytosine arabinoside dose of 25 mg/ml, we therefore used this concentration to assess the eects of MIP-1a on cytosine arabinoside induced cell death. We treated the cells with cytosine arabinoside (ara C) in the presence and absence of MIP-1a, at the permissive and restrictive temperatures for abl PTK activity (Figure 4) . Several points are of some interest. First the data clearly demonstrate that MIP-1a confers some degree of protection from the cytotoxic eect of ara C when the normal cells are grown at 338C or 38.58C and when the abl PTK cells are cultured at the restrictive temperature, 38.58C, for abl kinase activity. Second, the abl PTK FDCP-Mix cells grown at the permissive temperature for the kinase activity are more resistant to the cytotoxic eects of the drugs than are the corresponding cells cultured at the non-permissive temperature (these two values are signi®cantly dierent, P is less than 0.01).
Importantly, similar results were obtained when the experiments were repeated employing 5-¯uorouracil (which has dierent intracellular targets to ara C (Parker and Cheng, 1990)) (see Figure 5 ) and in all the abl PTK FDCP-Mix clones tested. Again we determined the concentration of 5-¯uorouracil (5 mg/ml) which induced approximately 50% cell Table 1 ) at the permissive and restrictive temperatures for abl PTK activity. Results shown are the mean+s.e.m. from four experiments. Experiments with control FDCP-Mix cells revealed that MIP-1a (100 ng/ml) gave a 34+4% inhibition of IL-3 stimulated [ 3 H]thymidine incorporation at 338C and a 24+5% inhibition at 38.58C (mean+s.e.m., n=3). DNA synthesis was determined using the [ 3 H]thymidine incorporation assay as in Table 2 . Brie¯y, cells were washed and then replated in Iscoves plus 2.5% (v/v) fetal calf serum, IL-3 (10 ng/ml) and MIP-1a at the appropriate concentration for 18 h prior to the addition of 1 mCi uorouracil. This agrees with other data showing that abl PTK can decrease the extent of cytotoxic-drug induced apoptosis in various cell systems (Bedi et al., 1995; Chapman et al., 1994) . MIP-1a does not confer protection on the drug induced death of abl PTK cells grown at the permissive temperature: rather, it partially sensitises them to the drug treatments.
MIP-1a receptor expression and coupling in Abl PTK FDCP-Mix cells
Previously we have shown that MIP-1a receptors are expressed on Ph + progenitor cells from patients with CML although these cells were shown to be nonresponsive to the growth inhibitory eect of MIP-1a.
We have now found that expression of abl PTK activity in the FDCP-Mix cells, as in CML cells, does not apparently in¯uence the number or anity of MIP-1a receptors (Table 3 and Chasty et al. (1995) ). To determine whether there is any degree of desensitisation of these receptors by switching from the restrictive to the permissive temperature in Abl PTK FDCP-Mix cells we next assayed one of the few intracellular signalling events known to be activated by MIP-1a, an increase in cytosolic Ca 3 H]thymidine suicide there was no signi®cant dierence in plating eciency. *** indicates a P value of less than 0.005, ** indicates a P value of less than 0.05 Figure 4 The ability of MIP-1a to protect against treatment with cytosine arabinoside in abl PTK FDCP-Mix and control FDCPMix cells at the permissive and restrictive temperatures for ts Abl PTK activity. Cells were treated with cytosine arabinoside (1 mg/ ml) for 30 min after pretreatment with IL-3 (10 ng/ml)+MIP-1a (150 ng/ml) for 2 h in serum free Iscoves medium. Similar results were seen in the presence of 10% (v/v) fetal calf serum. Results shown are the mean+s.e.m. from three separate experiments. ** indicates a P value less than 0.05. Plating eciency in control experiments in which cytosine arabinoside was excluded was not signi®cantly dierent to that described in the legend to Figure 4 Table 3 , there is a MIP-1a mediated increase in cytosolic Ca 2+ in control FDCP-Mix cells, at either the permissive or restrictive temperature, or the Abl PTK FDCP-Mix cells at the restrictive temperature. At the permissive temperature there was no MIP-1a stimulated increase in cytosolic Ca 2+ levels in Abl PTK FDCP-Mix cells. Thus MIP-1a signalling is, at least in part, desensitised in response to Abl PTK activation. However, other signal transduction events (as yet there is little conclusive data on signal transduction pathways activated by MIP-1a) may still be stimulated by this chemokine when Abl PTK is active. Selective desensitisation of speci®c signalling events or receptor pools could then explain the ability of MIP-1a to promote an increased sensitivity to MIP-1a (see Figures 4 and 5) .
The Abl PTK FDCP-Mix model system has yielded data which may describe mechanisms underlying dierences between Philadelphia chromosome positive, multipotent cell population and normal multipotent cells. For the ®rst time in a multipotent cell background we have been able to discern subtle dierences between cells expressing Abl PTK activity and those which are not. Plainly, this model provides a population of cells which are normally responsive to the growth inhibitor MIP-1a, a phenomenon found in very few other cell lines and this has allowed us to describe a direct eect of Abl PTK on the biology of FDCP-Mix cells. Further experiments should enable us to determine direct eects of Abl PTK on multipotent cells which help describe the molecular events associated with Chronic Myeloid Leukaemia more fully. For example, recently, it has been reported that MIP-1a can modulate the adhesion of CML progenitor cells to stroma suggesting that MIP-1a signalling pathways may not be completely uncoupled in CML cells (Bhatia et al., 1995) . These are a matter for further work. However, MIP-1a has now entered clinical trials as a putative chemoprotectant, aimed at reducing the marrow toxicity of various cytotoxic regimens (Dunlop et al., 1992; Lord et al., 1992) . Based on data presented here and elsewhere, clinical protocols for the treatments of patients with CML are now being developed, where MIP-1a will be tested for its ecacy to selectively protect the non-malignant haemopoietic progenitor cells whilst maintaining (or perhaps even increasing) the sensitivity of the leukaemic cells to cycle-active chemotherapeutic drugs. Thus selective desensitisation to the eects of a growth inhibitor is not only mechanistically signi®cant but also of potential clinical value.
Materials and methods
Maintenance of FDCP-Mix cell lines
FDCP-Mix cells were routinely cultured in Iscoves medium supplemented with 20% horse serum (v/v) and 2% (v/v) medium contained by the X63-Ag-653 cell line transfected with the IL-3 gene (mIL3CM) (Karasuyama and Melchers, 1988) and were maintained at 378C in a gassed incubator at 5% CO 2 in air. Abl PTK FDCP-Mix and FDCP-Mix mock transfected with the neomycin resistance gene only (see below) cells were cultured similarly to FDCP-Mix except 1 mg/ml Genticin (G418) was included in the culture medium and the cells were maintained at 38.58C. The day prior to each experiment, Abl PTK FDCP-Mix cells were placed at either the restrictive (38.58C) or permissive temperature (338C). Cellular viability was determined using trypan blue exclusion.
Generation of Abl PTK FDCP-Mix cells
Details of the derivation of the Abl PTK FDCP-Mix cell lines are described in Spooncer et al., 1994 . Brie¯y, FDCPMix cells were infected with a defective retrovirus using the myeloproliferative sarcoma virus based vector, pM5, carrying the neomycin phosphotransferase gene or the neomycin phosphotransferase gene plus the DP160 cDNA. The DP160 cDNA codes for the p160 v-abl protein and is temperature restricted for the function of the abl protein tyrosine kinase. At 38.58C the abl tyrosine kinase is inactive, at 338C it is active. The mock transfected cells carrying the neo gene were used as control cells in the experiments described below although similar results were obtained with non-transfected FDCP-Mix cells.
[ 3 H]thymidine incorporation assay DNA synthesis was determined using the [ 3 H]thymidine uptake assay described previously (Whetton et al., 1986) . Brie¯y, cells were washed and then replated in Iscoves plus 2.5% (v/v) fetal calf serum, 10 ng/ml IL-3 and various concentrations of MIP-1a for 18 h prior to the addition of 1 mCi [ 3 H]thymidine for 4 h. The cells were then harvested and taken for liquid scintillation counting.
Drug induced cell death assays and [
H]thymidine suicide assays
The assay was performed at either 338C or 38.58C for abl PTK FDCP-Mix and neo FDCP-Mix cells. Cells were washed and incubated with 10 ng/ml IL-3 and the appropriate concentration of MIP-1a for 2 h. Cells were then pulsed either with Iscoves, 1 mg/ml cytosine arabinofuranoside (Ara-c) or 5 mg/ml 5-¯uorouracil (5-FU) or high speci®c activity [
3 H]thymidine at 20 mCi/ml ] i ) was determined using fura-2 Ca 2+ indicator using the dual wavelength spectro¯uorometric method. Cells were loaded with fura-2-acetoxymethylester (5 mM for 30 min at either 38.58C or 338C, then washed and taken for [Ca 2+ ] i measurements as previously described (Heyworth et al., 1995) at either 38.58C or 338C.
I-MIP-1a binding to FDCP-Mix cells
FDCP-Mix and Abl PTK FDCP-Mix cells were incubated as described above at either 38.58C or 338C after which they were washed once in Iscoves medium (48C), centrifuged and resuspended in Phosphate Buered Saline (PBS), pH3, to remove agonist bound to receptors. Cells were then pelleted and resuspended in binding buer (DMEM containing 0.02% (w/v) sodium azide, 25 mM HEPES, 0.1% (w/v) BSA, pH 7.4, to a density of 1610 6 / ml. Binding of 125 I-MIP-1a was then assayed as previously described (Heyworth et al., 1990) using 125 I-MIP-1a of speci®c activity 2.0 mCi/mmol. Non-speci®c binding was calculated using an excess concentration of unlabelled MIP-1a (800 ng/ml).
Flow cytometric analysis of cell cycle distribution
Cell cycle distribution was determined using a propidium iodide stain. Brie¯y, cells were cultured as described above, after which they were ®xed in ice cold ethanol (70% v/v in PBS) for 30 min. Cells were then stained with propidium iodide (32 mM) for 1 min and analysed using a Becton Dickinson FacsVantage instrument. Results were analysed using Becton Dickinson Cell Fit Software.
